

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 December 2020 (24.12.2020)



(10) International Publication Number
WO 2020/254946 A1

(51) International Patent Classification:

C07D 413/06 (2006.01) A61K 31/497 (2006.01)
A61K 31/41 (2006.01) A61K 31/506 (2006.01)
A61K 31/4192 (2006.01) A61P 35/00 (2006.01)
A61K 31/4402 (2006.01)

(21) International Application Number:

PCT/IB2020/055589

(22) International Filing Date:

16 June 2020 (16.06.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/863,199 18 June 2019 (18.06.2019) US
62/953,223 24 December 2019 (24.12.2019) US
63/025,278 15 May 2020 (15.05.2020) US

(71) Applicants: **PFIZER INC.**, [US/US]; 235 East 42nd Street, New York, New York 10017 (US). **CTXT PTY LTD** [—/AU]; 305 Grattan Street, Parkville, Melbourne, 3000 (AU).

(72) Inventors: **BOZIKIS, Ylva Elisabet Bergman**; c/o Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052 (AU). **BRODSKY, Oleg**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **CAMERINO, Michelle Ang**; c/o Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052 (AU). **GREASLEY, Samantha Elizabeth**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **HOFFMAN, Robert Louis**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **KUMPF, Robert Arnold**; c/o Pfizer Inc., 10777 Science Center Drive, San


Diego, California 92121 (US). **KUNG, Pei-Pei**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **RICHARDSON, Paul Francis**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **STUPPLE, Paul Anthony**; c/o Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052 (AU). **SUTTON, Scott Channing**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer INC., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: BENZISOXAZOLE SULFONAMIDE DERIVATIVES



(I)

(57) Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ring A, R¹-R⁸, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*